The main use of homologous skin grafts or grafts of related bioproducts is in the treatment of severe burns. However, various new clinical and experimental sectors, in which this type of skin substitute can be useful, have recently emerged. The main new clinical indications for skin allografts include: skin loss, surgical wounds and bullous diseases. In these fields donor skin can be used for different purposes: as a physiological biological dressing to control pain and protect deep structures such as tendons, bones, cartilage and nerves, and to promote reepithelization with a significant reduction in healing time, and as skin substitute with dermal tissue to guide repair and make it as physiological as possible. In particular, skin bank bioproducts are currently used in the treatment of several conditions such venous and arterial leg ulcers, pressure ulcers, diabetic foot ulcers, pyoderma gangrenosum, post traumatic lesions, Mohs surgery, reconstructive surgery, wound cover in critical areas, aesthetic surgery, congenital epidermolysis bullosa and Lyell's syndrome. Skin bank bioproducts have also been used for experimental indications, to study in vitro toxicology and in vitro skin biology. Recently the demonstration that de-epidermized dermis (DED) has all the characteristics of an excellent dermal substitute into which various types of cells can be introduced and made to develop, opens exciting new possibilities of research in the field of wound healing and tissue engineering. Our preliminary observations seems to indicate that CD 34+ stem cells from umbilical cord blood can survive in DED and in a few weeks populate collagen bundles. The observation of tubular structures without lumina close to collagen bundles as well as clusters of epithelioid or fibroblast-shaped cells may represent aspects of differentiation of CD 34+ stem cells. More detailed and sophisticated studies are clearly needed to answer all the questions that these initial observations pose. Anyway the 3-dimensional model proposed seems to be suitable for the study of the behaviour of peripheral CD 34+ and perhaps also other types of stem cells in 3-dimensional dermal matrix.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2004.07.025DOI Listing

Publication Analysis

Top Keywords

skin bank
12
bank bioproducts
12
stem cells
12
skin
10
homologous skin
8
skin grafts
8
skin substitute
8
34+ stem
8
collagen bundles
8
cells
5

Similar Publications

Food Allergy Prevalence in Two Population-Based UK Cohorts Born 12 Years Apart.

Clin Exp Allergy

January 2025

Section of Allergy and Clinical Immunology, Children's Hospital Colorado, University of Colorado, Aurora, Colorado, USA.

Background: Adverse food reactions include food allergy (FA; immune-mediated) and food intolerances (non-immune-mediated). FA are classified into IgE- and non-IgE-mediated FA. There is limited information available about changes in FA prevalence over time.

View Article and Find Full Text PDF

Tibetan donkeys inhabit the harsh environment of the Qinghai-Tibet Plateau. Research on serum metabolites related to their high-altitude adaptation is limited compared to other livestock. We used liquid chromatography-mass spectrometry (LC-MS) to analyze serum samples from healthy adult donkeys in Shigatse, Changdu, and Dezhou to evaluate the effects of high altitudes on serum metabolites.

View Article and Find Full Text PDF

26 Years of Skin Banking in Finland.

Eur Burn J

December 2024

Helsinki Burn Centre, Department of Plastic Surgery, Helsinki University Hospital and University of Helsinki, 00029 Helsinki, Finland.

Autologous skin grafts are the gold standard for definitive wound coverage in burn care, but allograft skin grafts are essential for providing temporary coverage in cases of extensive burns. The Helsinki Skin Bank, established in 1995 at the Helsinki Burn Centre, is Finland's only licensed skin bank, serving a population of 5.5 million.

View Article and Find Full Text PDF

Background: RelabotulinumtoxinA (RelaBoNT-A) is a complex-free, ready-to-use, liquid botulinum toxin A.

Objective: Efficacy/safety of RelaBoNT-A treatment for lateral canthal lines (LCL).

Methods: Randomized adults received RelaBoNT-A (30 U/side; n = 230) or placebo (n = 73) during a 6-month, double-blind, Ph3 study (Relabotulinumtoxin Aesthetic Development Study-2 [READY-2]).

View Article and Find Full Text PDF
Article Synopsis
  • Atopic dermatitis (AD) and type 2 diabetes mellitus (T2DM) are different conditions, but this study reveals shared molecular mechanisms and chronic inflammation connecting them.
  • Using advanced analyses, researchers identified key genes like LTF, LTB4R, and CCR1 that are upregulated in both diseases, suggesting they could be used as biomarkers.
  • Additionally, potential therapeutic candidates Dioscin, Camptothecin, and Albamycin were found to bind effectively to CCR1, highlighting new avenues for treatment.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!